CAS 954389-09-4

Formel: C28H23F7N6O4S2

InChl: InChI=1S/C28H23F7N6O4S2/c29-19-11-15(1-8-21(19)45-28(33,34)35)12-37-25(42)20-14-40(26-39-24-22(46-26)13-36-23(38-24)16-2-3-16)9-10-41(20)47(43,44)18-6-4-17(5-7-18)27(30,31)32/h1,4-8,11,13,16,20H,2-3,9-10,12,14H2,(H,37,42)/t20-/m1/s1

InChI Key: JQLOVYLALGSISI-HXUWFJFHSA-N

SMILES: C1CC1C2=NC=C3C(=N2)N=C(S3)N4CCN([C@H](C4)C(=O)NCC5=CC(=C(C=C5)OC(F)(F)F)F)S(=O)(=O)C6=CC=C(C=C6)C(F)(F)F

JTK-853

CAS: 954389-09-4

JTK-853: novel non-nucleoside HCV polymerase inhibitor with strong antiviral activity (EC50: 0.38 μM genotype 1a, 0.035 μM 1b).

Formel: C₂₈H₂₃F₇N₆O₄S₂

Reinheit: 98%

Farbe und Form: Solid

Molekulargewicht: 704.64

Ref: TM-T15631

JTK-853

CAS: 954389-09-4

JTK-853 is a histidine-based compound that has potent inhibitory activity against hepatitis B virus (HBV) and hepatitis C virus (HCV). It binds to the replicon and prevents RNA polymerase from transcribing viral DNA. JTK-853 also inhibits human immunodeficiency virus (HIV) by preventing reverse transcriptase from synthesizing DNA, but has no effect on human serum albumin. The drug is currently in clinical development for HBV and HCV infections. Strategies to prevent resistance include using genotype information to select patients who are likely to be responsive to JTK-853, or using non-nucleoside inhibitors as an adjunct therapy for those who are resistant.

Formel: C₂₈H₂₃F₇N₆O₄S₂

Reinheit: Min. 95%

Molekulargewicht: 704.6 g/mol

Ref: 3D-ENB38909